Latest pharmaceutical industry Stories
CHENGDU, China, May 5, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the third quarter of fiscal year 2013 ending March 31, 2013 to be held at 9:00 a.m. ET on Wednesday, May 15(th), 2013. Interested parties may...
Integral BioSystems will exhibit and offer its drug development expertise to attendees at the ARVO Annual Meeting at the Washington State Convention Center in Seattle, WA from May 5, 2013 through May 9, 2013 in Exhibitor Booth #517. Bedford, MA (PRWEB) May 05, 2013 The 2013 Meeting of the Association for Research and Vision in Ophthalmology, being held at the Washington State Convention Center in Seattle, WA combines a wide range of talks from commercial and academic figures in...
GAITHERSBURG, Md., May 4, 2013 /PRNewswire/ -- MedImmune announced today it will conduct seven poster and/or presentations at the Pediatric Academic Societies (PAS) Meeting at the Walter E. Washington Convention Center in Washington DC, May 4-7, 2013. These abstracts advance the body of existing data and knowledge around influenza and respiratory syncytial virus (RSV) prevention, highlighting MedImmune's continued commitment to patient health. MedImmune posters to be presented at...
EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a class 2 medical device, with indications for use specifically for managing ophthalmic clinical trial data. DAVIS, CA and MADISON, WI (PRWEB) May 03, 2013 EyeKor, LLC, a new service provider dedicated to the support of ocular clinical trials, announces FDA 510k clearance of its EXCELSIOR™ image management software as a...
“Cell Culture: The Market for Media, Sera and Reagents, 5th Edition” is the new market research report added to ReportsnReports.com store. Dallas, TX (PRWEB) May 04, 2013 The growth in bio-pharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture techniques have been applied to production systems for only about 26 years. The cell culture...
Expands Industry-Leading, Software-as-a-Service Social Media Listening Platform DANBURY, Conn., May 3, 2013 /PRNewswire-iReach/ -- IMS Health today announced the acquisition of Semantelli Corporation, a Bridgewater, N.J.-based social media analytics company, to extend its marketing and consumer engagement capabilities for healthcare organizations around the world. Semantelli offers clients a robust set of cloud-based tools that automate the collection of healthcare-specific social...
BOSTON, May 3, 2013 /PRNewswire/ -- Bio-Optronics, Inc. and Schulman Associates IRB are proud to announce their partnership and their newly integrated regulatory compliance module for the Clinical Conductor Enterprise CTMS application. This collaboration offers Clinical Conductor Enterprise CTMS users streamlined IRB interactions from one centralized location. The new module will be officially unveiled during the MAGI East Clinical Research Conference in Boston, MA on May 5(th). "One...
SAN DIEGO, May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, today provided the following letter to shareholders: Dear Shareholder: A number of stockholders have been asking...
SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology. Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product...
REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific...
